No Data
No Data
X4 Pharmaceuticals Updates Corporate Presentation for Investors
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $5 Price Target
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Swayampakula Ramakanth maintains $X4 Pharmaceuticals(XFOR.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rat
X4 Slips After Mid-stage Data for Lead Drug in Neutropenia
X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment
Express News | X4 Pharmaceuticals: Screening Patients for Enrollment Into 4Ward Study
No Data